publication date: Feb. 9, 2018

CRUK names ten finalists for £20m Grand Challenge

Cancer Research UK has shortlisted ten multidisciplinary, international teams for what amounts to the second leg of competition for Grand Challenge awards.

Each of the teams will now receive £30,000 in seed funding to prepare up their applications for interviews later this year.

They are competing for the £20m Grand Challenge funding award (The Cancer Letter, July 21).

The ten team were chosen from a pool of 134 applications from 41 countries.

The challenge, now in its second phase, plans to give out several £20 million awards over five years to researchers who would be willing to address one of eight challenge areas.

The strategy—borrowed from mathematics—is to identify the most significant barriers to making progress and challenge scientists all over the world to join forces to answer them. The Grand Challenge provides the largest single response-mode grants available in cancer research, CRUK said.

The approach of focusing the attention of an entire discipline on a specific set of questions originated with David Hilbert, a German mathematician. In 1900, Hilbert identified 23 problems and presented 10 of them at the Paris conference of the International Congress of Mathematicians. His list of challenges had in effect set the course for research in mathematics through much of the 20th century.

Winners will be determined by a panel that includes:

Richard Klausner, a biotechnology entrepreneur, former NCI director, and chair of the Grand Challenge advisory panel;

Adrian Bird, the Buchanan Professor of Genetics at the University of Edinburgh; 

Suzanne Cory, of the Walter and Eliza Hall Institute of Medical Research; 

Ed Harlow, professor … Continue reading CRUK names ten finalists for £20m Grand Challenge

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.